|

Estimated Read Time:

1–2 minutes

Polygenic Scores in Research, Clinical Classification, and Prediction—Opportunities and Hurdles for Translation

2025 PRESENTER PROFILES

Polygenic Scores in Research, Clinical Classification, and Prediction—Opportunities and Hurdles for Translation

Sunday, June 22, at 4:30 p.m. CT

Room W190 A • McCormick Place Convention Center

Polygenic Scores in Type 1 Diabetes

Aaron Deutsch, MD
Aaron Deutsch, MD

Aaron Deutsch, MD

Instructor,
Massachusetts General Hospital

What is your presentation about?
This presentation will discuss current uses of polygenic scores as applied to type 1 diabetes. We will demonstrate how polygenic scores can identify individuals at high risk of developing type 1 diabetes in the future. We will also demonstrate how type 1 diabetes polygenic scores can differentiate among various forms of diabetes, including type 1, type 2, monogenic, or atypical forms of diabetes. Finally, we will discuss challenges in implementing type 1 diabetes polygenic scores in diverse populations.

How do you hope your presentation will impact diabetes research or care?
We hope this presentation will demonstrate how type 1 diabetes polygenic scores can already be used in clinical practice. In the future, polygenic scores may be integrated into newborn screening programs, to identify candidates for monoclonal antibody therapies that delay the onset of type 1 diabetes.

How did you become involved with this area of diabetes research or care?
As an adult endocrinologist, I specialize in the care of patients with diabetes. I am particularly interested in the heterogeneity of diabetes, especially across diverse populations. Genetic analysis is one tool that can help decipher disease heterogeneity.